Menno R Smit, Eric O Ochomo, Ghaith Aljayyoussi, Titus K Kwambai, Bernard O Abong'o, Tao Chen, Teun Bousema, Hannah C Slater, David Waterhouse, Nabie M Bayoh, John E Gimnig, Aaron M Samuels, Meghna R Desai, Penelope A Phillips-Howard, Simon K Kariuki, Duolao Wang, Steve A Ward, Feiko O Ter Kuile
BACKGROUND: Ivermectin is being considered for mass drug administration for malaria due to its ability to kill mosquitoes feeding on recently treated individuals. However, standard, single doses of 150-200 μg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal effect (<7 days). Because ivermectin is well tolerated up to 2000 μg/kg, we aimed to establish the safety, tolerability, and mosquitocidal efficacy of 3 day courses of high-dose ivermectin, co-administered with a standard malaria treatment...
March 27, 2018: Lancet Infectious Diseases